Key result
Elevated CA125 and NT-proBNP linked to ~675% greater 1-year mortality risk versus low levels.
Why the study?
The study was designed to explore the prognostic value of serum CA125 combined with NT-proBNP in patients with acute heart failure.
Does the combination of CA125 and NT-proBNP predict 1-year all-cause death in patients with acute heart failure?
Population
213 patients with AHF
Comparison
Stratification across four groups based on CA125 and NT-proBNP cut-off levels
Design
Prospective observational study
Follow-up
12 months
Authors
Loading...
May aid high-risk identification in heart failure; leaves open incremental prognostic value and needs validation.
Cohort (n=213)
Does the combination of CA125 and NT-proBNP predict 1-year all-cause death in patients with acute heart failure?
Hazard Ratio: 7.75 (95% CI 3.09–19.45)
Absolute Event Rate: 56.9% vs 6%
p-value: p=<0.001
The combination of elevated CA125 and NT-proBNP serves as a strong independent predictor of 1-year mortality in patients with acute heart failure, improving risk stratification.
Chen et al. (2020) conducted a cohort in Acute heart failure (n=213). Elevated CA125 (≥47.6 U/ml) and NT-proBNP (≥3790 pg/ml) vs. CA125 <47.6 U/ml and NT-proBNP <3790 pg/ml was evaluated on 1-year all-cause death (HR 7.75, 95% CI 3.09-19.45, p=<0.001). Elevated CA125 combined with NT-proBNP was associated with a significantly higher risk of 1-year all-cause death compared to low levels of both (56.9% vs 6.0%; HR 7.75; 95% CI 3.09-19.45; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: